Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
Abstract
Aims: Hypoglycemia is a common adverse effect of sulfonylurea oral hypoglycemic agents. Impaired metabolism of sulfonylureas due to gene polymorphisms in the metabolic enzyme CYP2C9 might lead to hypoglycemia. In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide. Materials & methods: A total of 92 Type 2 diabetes mellitus (T2DM) patients receiving sulfonylurea and reporting drug-associated hypoglycemia, and 84 T2DM patients receiving sulfonylurea and having never experienced hypoglycemia were included in the study. A sample of 283 nondiabetic controls that had been genotyped earlier served as a second control group. CYP2C9*2 and *3 alleles were detected by use of PCR-RFLP analysis. Results: Frequencies of CYP2C9*1/*3 genotype and CYP2C9*3 allele were significantly lower in T2DM patients than nondiabetic controls (p = 0.003 and p = 0.017, respectively). A total of 11 out of 92 subjects (12%) experiencing hypoglycemia carried the CYP2C9*3 allele, as opposed to only 1 out of 84 subjects (1.2%) free of sulfonylurea-induced hypoglycemia. In a model adjusted for age, BMI, mean daily dose of sulfonylurea, duration of T2DM and renal function, CYP2C9*1/*3 genotype increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 1.687; p = 0.011). However, no differences in CYP2C9*2 allele frequency between the two groups were found. Discussion & conclusion: The presence of CYP2C9*3 appears to be protective for development of T2DM. Furthermore, in T2DM patients, CYP2C9*3 increases the risk of hypoglycemia when they are treated with sulfonylureas, possibly due to impaired metabolism of these drugs. CYP2C9 genotyping might thus be a useful tool for predicting adverse effects caused by sulfonylureas and help clinicians in safer prescribing of oral hypoglycemic agents. The potential T2DM protective effect of CYP2C9*3 allele requires further investigation.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
Bibliography
- 1 Amiel SA, Dixon T, Mann R, Jameson K: Hypoglycaemia in Type 2 diabetes. Diabet. Med.25,245–254 (2008).
- 2 Murata GH, Duckworth WC, Hoffman RM et al.: Hypoglycemia in Type 2 diabetes: a critical review. Biomed. Pharmacother.58,551–559 (2004).
- 3 Rendell M: The role of sulphonylureas in the management of Type 2 diabetes mellitus. Drugs64,1339–1358 (2004).
- 4 Burge MR, Schmitz-Fiorentino K, Fischette C, Qualls CR, Schade DS: A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in Type 2 diabetes mellitus. JAMA279,137–143 (1998).
- 5 Salas M, Caro JJ: Are hypoglycaemia and other adverse effects similar among sulphonylureas? Adverse Drug React. Toxicol. Rev.21,205–217 (2002).
- 6 Holstein A, Egberts EH: Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes111,405–414 (2003).
- 7 Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J: Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet.44,1209–1225 (2005).▪▪ Detailed review of the implication of CYP2C9 enzyme in the metabolism of oral antidiabetic drugs.
- 8 Becker ML, Visser LE, Trienekens PH et al.: Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in Type II diabetes mellitus. Clin. Pharmacol. Ther.83,288–292 (2008).▪ Pharmacokinetic study suggesting that carriers of CYP2C9 defective alleles require lower doses of sulfonylureas to regulate their serum glucose levels.
- 9 Suzuki K, Yanagawa T, Shibasaki T et al.: Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with Type 2 diabetes. Diabetes Res. Clin. Pract.72,148–154 (2006).
- 10 Niemi M, Cascorbi I, Timm R et al.: Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther.72,326–332 (2002).▪ Pharmacokinetic study showing the clinical significance of CYP2C9 null alleles genotyping in sulfonylurea treatment.
- 11 Wang R, Chen K, Wen SY, Li J, Wang SQ: Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin. Pharmacol. Ther.78,90–92 (2005).▪ Pharmacokinetic study showing that CYP2C9 polymorphisms may predict the optimal glimepiride dose in Type 2 diabetes mellitus patients.
- 12 Yin OQ, Tomlinson B, Chow MS: CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin. Pharmacol. Ther.78,370–377 (2005).▪ Pharmacokinetic study showing that CYP2C9 polymorphisms may predict the optimal glyburide dose in Type 2 diabetes mellitus patients.
- 13 Zhang Y, Si D, Chen X et al.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br. J. Clin. Pharmacol.64,67–74 (2007).
- 14 Manolopoulos VG: Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin. Chem. Lab. Med.45,801–814 (2007).▪ Comprehensive review of the most important gene polymorphisms with clinical value and their possible applications in drug prescribing.
- 15 Arvanitidis K, Ragia G, Iordanidou M et al.: Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam. Clin. Pharmacol.21,419–426 (2007).
- 16 Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev.54,1257–1270 (2002).
- 17 Kirchheiner J, Bauer S, Meineke I et al.: Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics12,101–109 (2002).▪ Pharmacokinetic study showing the effect of CYP2C9 polymorphisms on tolbutamide clearance and elimination half-life.
- 18 Holstein A, Plaschke A, Ptak M et al.: Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol.60,103–106 (2005).▪▪ Seminal study introducing the association of CYP2C9 polymorphisms with severe hypoglycemia.
- 19 Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics10,43–49 (2009).
- 20 American Diabetes Association Workgroup on Hypoglycemia: Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care28,1245–1249 (2005).▪ Clear and comprehensive set of instructions and criteria on how to define and report hypoglycemia.
- 21 Scheen AJ: Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf.28,601–631 (2005).
- 22 Kim YM, Yoo SH, Kang RY et al.: Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am. J. Health Syst. Pharm.64,166–175 (2007).
- 23 Siguret V, Pautas E, Gouin-Thibault I: Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam. Horm.78,247–264 (2008).
- 24 Elbekai RH, El-Kadi AO: Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol. Ther.112,564–587 (2006).
- 25 Yu BN, Luo CH, Wang D et al.: CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin. Chim. Acta348,57–61 (2004).
- 101 Diagnosis and Classification of Diabetes Mellitus: New Criteria www.aafp.org/afp/981015ap/mayfield.html
